Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin- 3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3, 6-dihydropyridine-1(2H)-carboxamide (FTIDC)

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 1144-1153

  Suzuki, Gentaroh ^a   Kimura, Toshifumi ^a   Satow, Akio ^a   Kaneko, Naoki ^a   Fukuda, Junko ^a   Hikichi, Hirohiko ^a   Sakai, Naoko ^a   Maehara, Shunsuke ^a   Kawagoe Takaki, Hiroko ^a   Hata, Mikiko ^a   Azuma, Tomoko ^a   Ito, Satoru ^a   Kawamoto, Hiroshi ^a   Ohta, Hisashi ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 (2 FLUOROPYRIDIN 3 YL) 5 METHYL 1H 1,2,3 TRIAZOL 4 YL] N ISOPROPYL N METHYL 3,6 DIHYDROPYRIDINE 1(2H) CARBOXAMIDE; GLUTAMATE RECEPTOR 1; GLUTAMATE RECEPTOR 1A; GLUTAMATE RECEPTOR 2; GLUTAMATE RECEPTOR 4; GLUTAMATE RECEPTOR 6; GLUTAMATE RECEPTOR 8; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM CELL LEVEL; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BENZIMIDAZOLES; BINDING, COMPETITIVE; CALCIUM SIGNALING; CELL LINE; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; HUMANS; INOSITOL PHOSPHATES; MALE; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; MOTOR ACTIVITY; NAPHTHALENES; POINT MUTATION; QUISQUALIC ACID; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; THIAZOLES; TRANSFECTION; TRIAZOLES;

EID: 34248667888     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.116574     Document Type: Article

References (40)

1. Barton ME and Shannon HE (2005) Behavioral and convulsant effects of the (S) enantiomer of the group I metabotropic glutamate receptor agonist 3,5-DHPG in mice. Neuropharmacology 48:779-787.
2. Belozertseva IV, Kos T, Popik P, Danysz W, and Bespalov AY (2007) Antidepressantlike effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 17:172-179.
3. Brandish PE, Hill LA, Zheng W, and Scolnick EM (2003) Scintillation proximity assay of inositol phosphates in cell extracts: high-throughput measurement of G-protein-coupled receptor activation. Anal Biochem 313:311-318.
4. Carroll FY, Stolle A, Beart PM, Voerste A, Brabet I, Mauler F, Joly C, Antonicek H, Bockaert J, Müller T, et al. (2001) BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol 59:965-973.
5. Comer JEA (2003) Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability (van de Waterbeemd H, Lennernäs H, and Artursson P eds) pp 21-45, Wiley-VCH, Weinheim, Germany.
6. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
8. El-Kouhen O, Lehto SG, Pan JB, Chang R, Baker SJ, Zhong C, Hollingsworth PR, Mikusa JP, Cronin EA, Chu KL, et al. (2006) Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br J Pharmacol 149:761-774.
9. Flor PJ, Lindauer K, Püttner I, Rüegg D, Lukic S, Knöpfel T, and Kuhn R (1995) Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 2. Eur J Neurosci 7:622-629.
10. Goudet C, Gaven F, Kniazeff J, Vol C, Liu Jiangfeng, Cohen-Gonsaud M, Acher F, Prézeau L, and Pin JP (2004) Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc Natl Acad Sci USA 101: 378-383.
11. Horton RM, Hunt HD, Ho SN, Pullen JK, and Pease LR (1989) Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-67.
12. Kawamoto H, Ito S, Satoh A, Nagatomi Y, Hirata Y, Kimura T, Suzuki G, Sato A, and Ohta H (2006) inventors; Banyu Pharmaceutical Co., Ltd., assignee. Biaryl derivatives. World patent WO2006/004142. 2006 Jan 12.
13. Kohara A, Toya T, Watabiki T, Nagakura Y, Shitaka Y, Hayashibe S, Kawabata S, and Okada M (2005) Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3- dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1. J Pharmacol Exp Ther 315:163-169.
14. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, and Morikawa K (2000) Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature (Lond) 407:971-977.
15. Lavreysen H, Wouters R, Bischoff F, Pereira SN, Langlois X, Blokland S, Somers M, Dillen L, and Lesage ASJ (2004) JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 47:961-971.
16. Layton ME (2005) Subtype-selective noncompetitive modulators of metabotropic glutamate receptor subtype 1 (mGluR1). Curr Top Med Chem 5:859-867.
17. Li L, Tomlinson R, Wang Y, Tsui HCT, Chamberlain MJ, Johnson MP, Baez M, Vannieuwenhze MS, Zia-Ebrahimi M, Hong EJ, et al. (2002) A novel series of potent and selective non-competitive antagonists of metabotropic glutamate receptor 1. Neuropharmacology 43:295.
18. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, and Kuhn R (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55:453-461.
19. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, et al. (2003) ( - )-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 45:895-906.
20. Mathiesen JM, Svendsen N, Bräuner-Osborne H, Tomsen C, and Ramirez MT (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138:1026-1030.
21. Malherbe P, Kratochwil N, Knoflach F, Zenner MT, Kew JNC, Kratzeisen C, Maerki HP, Adam G, and Mutel V (2003) Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J Biol Chem 278:8340-8347.
22. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83-244.
23. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, et al. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther 309:568-577.
24. 3H]L-quisqualic acid and recombinant receptors. Z Naturforsch [C] 57:348-355.
25. Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Azuma T, Ichikawa D, Nambu H, Iguchi T, Iwasawa Y, and Ohta H (2000) In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol 402:45-53.
26. Pagano A, Rüegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezéau L, Carroll F, Pin JP, et al. (2000) The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropanchromen-1acarboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275:33750-33758.
27. Palucha A and Plic A (2005) The involvement of glutamate in the pathophysiology of depression. Drug News Perspect 18:262-268.
28. Pin JP, Colle CD, Bessis AS, and Acher F (1999) New perspectives for the development of selective metabotropic glutamate receptor ligands. Eur J Pharmacol 375:277-294.
29. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, Vernier JM, et al. (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64:798-810.
30. Simon AB and Gorman JM (2006) Advances in the treatment of anxiety: targeting glutamate. NeuroRx 3:57-68.
31. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, and Schreiber R (2003) Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioral characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257-277.
32. Soloviev MM, Ciruela F, Chan WY, and McIlhinney RAJ (1999) Identification, cloning and analysis of expression of a new alternatively spliced form of the metabotropic glutamate receptor mGluR1 mRNA. Biochim Biophys Acta 1446: 161-166.
33. +-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sci USA 89:10955-10959.
34. Tanabe Y, Masu M, Ishii T, Shigemoto R, and Nakanishi S (1992) A family of metabotropic glutamate receptors. Neuron 8:169-179.
35. Varney MA and Gereau RW IV (2002) Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr Drug Targets 1:283-296.
36. Varney MA and Suto CM (2000) Discovery of subtype-selective metabotropic glutamate receptor ligands using functional HTS assays. Drug Discov Today 5 (Suppl): 20-26.
37. Wu S, Wright RA, Rockey PK, Burgett SG, Arnold JS, Rosteck PR Jr, Johnson BG, Schoepp DD, and Belagaje RM (1998) Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res 53:88-97.
38. 2+ receptor. FEBS Lett 448:180-184.
39. Zheng GZ, Bhatia P, Daanen J, Kolasa T, Petal M, Latshaw S, El-Kouhen OF, Chang R, Uchic ME, Miller L, et al. (2005) Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J Med Chem 48:7374-7388.
40. Zhu H, Ryan K, and Chen S (1999) Cloning of novel splice variants of mouse mGluR1. Brain Res Mol Brain Res 73:93-103.